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Abstract
Background: Despite low incidence, ovarian cancer is the fifth leading cause of cancer deaths and it has the highest
mortality rate of all gynecologic malignancies among US women. The mortality rate would be reduced with an early
detection marker. The folate receptor alpha (FRa) is one logical choice for a biomarker because of its prevalent
overexpression in ovarian cancer and its exclusive expression in only a few normal tissues. In prior work, it was observed
that patients with ovarian cancer had elevated serum levels of a protein that bound to a FRa-specific monoclonal antibody
relative to healthy individuals. However, it was not shown that the protein detected was intact functional FRa. In the current
study, the goal was to determine whether ovarian cancer patients (n = 30) had elevated serum levels of a fully functional
intact FRa compared to matched healthy controls (n = 30).
Methodology/Principal Findings: FRa levels in serum were analyzed by two methods, immunoblotting analysis and a
radiolabeled folic acid-based microfiltration binding assay. Using the immunoassay, we observed that levels of FRa were
higher in serum of ovarian cancer patients as compared to controls. Similar results were also observed using the
microfiltration binding assay, which showed that the circulating FRa is functional. Importantly, we also found that the levels
of FRa were comparable between early and advanced stage patients.
Conclusions: Our results demonstrate that ovarian cancer patients have elevated levels of functional intact FRa. These
findings support the potential use of circulating FRa as a biomarker of early ovarian cancer.
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adenomyosis, uterine fibroids, pelvic inflammatory disease,
menstruation, and benign ovarian cysts. CA-125 is also associated
with other malignant conditions such as pancreatic, breast, lung,
gastric, and colonic cancers [4]. Although the CA-125 is helpful in
the follow-up of the patient’s chemotherapy and in detecting early
relapse in patients with already known ovarian cancers, it is not
useful for identifying early stage disease [5].
The folate receptor a (FRa), a 38–40 kDa molecule, is a well
characterized member of the folate receptor (FR) family with high
affinity for folates. FRa is anchored to cell membranes through a
glycosylphosphatidylinositol moiety and transports folates via an
endocytic process [6]. FRa exhibits limited normal tissue distribution, with measurable expression restricted to the apical surfaces of a
few epithelia, predominantly in the lung, kidney, and choroid
plexus, but is overexpressed in a spectrum of solid tumors, including
ovarian cancer, non small cell lung cancer, breast cancer, kidney
cancer and in high-grade osteosarcoma [7–10]. This overexpression of high affinity FRa in some cancers may have arisen
to meet cellular requirements for DNA synthesis and growth [11].

Introduction
Ovarian cancer is the fifth leading cause of cancer death and
has the highest mortality rate of all gynecologic malignancies
among US women with an estimated 21,650 new cases and an
anticipated .15,500 deaths in 2008 [1]. The majority of patients
with ovarian cancer present with advanced disease (stages III–IV)
and have a 5-year survival of typically ,30%. The fact that
survival of patients with stages I–II disease ranges from 60%–90%,
depending on tumor grade [1,2] suggests the potential for a high
cure rate with earlier disease detection. Since physical symptoms
are absent in early stages of ovarian cancer, efforts are being made
to develop assays for blood or tissue biomarkers.
Although the serum CA-125, an ovarian cell surface glycoprotein (i.e. a mucin) of unknown biological significance, is elevated in
.80% of patients with advanced epithelial ovarian cancer, this
marker has a positive predictive value of ,10% in early stage
disease [3]. Furthermore, CA-125 is also associated with various
non-malignant conditions, such as pregnancy, endometriosis,
PLoS ONE | www.plosone.org
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In addition to its cell surface localization, FRa can also be shed
into the blood. Shedding was initially identified during the
development of the folate radioligand binding assays which used
purified cell-free FR as a binding protein. In these studies it was
noted that there was often a large discrepancy in the assessment of
total serum folate when assayed after heat extraction as compared
to native serum [12]. When shed, FRa will bind circulating folate,
since the affinity is in the nM range. Now it is well understood that
shedding complicates the interpretation of serum folate assays and
possibly masks the presence of functional receptor unless an acid
treatment is employed to release the endogenous folate and allow
FRa saturation with the radiolabeled folic acid. This discrepancy
in folic acid levels between native and heat extracted serum led to
the identification of circulating FRa in some samples of umbilical
cord blood and in some of the maternal serum [13]. Importantly,
FRa released from normal epithelial cells should not contribute to
FRa levels in the serum, since the receptor is invariably localized
to the apical surface of a polarized epithelium where its shedding
will deliver the free receptor into a lumen that naturally drains
from the body through its own orifice.
Recent studies suggest that FRa may also be shed into the blood
from tumors, which offers an opportunity to access and measure it
as a tumor marker of early stage cancer. The prevalent expression
of FRa in ovarian cancer, among all stages, has stimulated interest
in applying it as a therapeutic target and biomarker [14]. The goal
of the current study was to determine if intact functional FRa is
shed into the circulation and to evaluate its potential as a
circulating biomarker. This goal is supported by prior work which
showed that ovarian cancer patients have elevated levels of a
serum protein that react with anti-FRa antibodies [15]. What
remained to be answered was whether the antibodies detected
whole FRa and whether the detected protein was a functional
folate receptor (FR). Thus, in the present study, the levels of
circulating FRa in the blood of patients with ovarian cancer were
examined using a 3H-FA-based microfiltration assay which was
developed to detect functional FRa. Additionally, an immunoblot
assay was employed to confirm the presence of the specific whole
FRa protein. As will be shown, ovarian cancer patients
demonstrate elevated levels of FRa in the circulation supporting
its potential use as a disease biomarker.

Table 1. Tumor and patient characteristics.

Tumor histology
Serous

18 (60)

Serous borderline

3 (10)

Endometrioid

3 (10)

Clear cell

1 (3)

Mucinous borderline

3 (10)

Mixed

1 (3)

Transitional cell

1 (3)

Grade
1

2 (7)

2

2 (7)

3

15 (50)

4

6 (20)

FIGO stage
Stage I

13 (43)

Stage II

2 (7)

Stage III

6 (20)

Stage IV

9 (30)

Debulking status
Optimal

25 (83)

Sub-optimal

5 (17)

FRa expression
High

27 (90)

Low

3 (10)

doi:10.1371/journal.pone.0006292.t001

(3H-FA,1 mCi/ml) was purchased from American Radiolabeled
Chemicals (St. Louis, Missouri), and Ready-Safe liquid scintillation
cocktail was from Beckman Coulter. Anti-FRa antibodies,
MOv18/ZEL and F5753 were from Alexis Biochemicals (San
Diego, CA) and US Biological (Swampscott, MA), respectively.

Preparation of tumor cell lysates and cell culture
supernatants as sources of FRa

Materials and Methods
Ethics Statement

KB cells are human nasopharyngeal epidermoid carcinoma
cells that express high levels of FRa [16–18]. KB cells were
cultured in media consisting of folate-free RPMI 1640, supplemented with 55 mM 2-mercaptoethanol, 2 mM L-glutamine,
1 mM sodium pyruvate, 10 mM HEPES buffer, 100 IU/ml
penicillin, 100 mg/ml streptomycin and 10% fetal bovine serum.
Supernatants were prepared by centrifugation of conditioned
media at 4uC to remove unanchored cells. Aliquots of 4-day
supernatants were stored at 280uC to be used as a source of noncell associated FRa. Cell lysates were prepared from confluent KB
monolayers by repeated freeze-thaw cycles followed by centrifugation to remove debris. For both supernatants and cell lysates,
protein concentrations were determined by optical density. MCF7 human breast cancer cells were used as a FRa2negative control
and prepared similarly to KB cells. Lysates (5–10 mg of lysates) and
supernatants (10–20 mL) were used for assay development and as
controls.

The Mayo Clinic IRB approved the study and written informed
consent was obtained from all the subjects.

Subjects
Each ovarian cancer case was first matched to a female control
on blood draw within 6 months (all 30 cases matched successfully),
and then age within 5 years. Twenty-nine cases were successfully
matched. The 30th case was matched on blood draw within 6
months and age within 9 years to an eligible control. Eligible cases
were patients, over age 20, with histologically confirmed primary
epithelial ovarian cancer. A 40-mL (pre-operative) blood sample
was collected, processed, aliquoted, and stored at 280uC as serum.
The mean age (6SEM) of the age-matched healthy female donors
and patients were 6163 and 60.6363 years respectively. Other
patient and tumor characteristics are presented in Table 1.

Supplies and reagents

3

H-folic acid binding assay

Folic acid was obtained from Alexis Biochemicals. Centrifuge
filters (10,000 dalton cutoff) were purchased from Millipore
(Burlington, MA). Tritiated folic acid [3,5,7,9-3H] sodium salt,
PLoS ONE | www.plosone.org
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Measurement of folate receptors in cases and controls was a
variation of a previously described method [19]. Samples (10 ml)
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attributes of the microcentrifuge filtration assay. KB cell
supernatant samples were incubated with increasing amounts of
3
H-FA in the absence and presence of excess cold FA and then
measured the recovery of bound 3H-FA. As shown in Figure 1A,
between 10 and 120 nmol/L 3H-FA, the total binding increased in
a linear fashion. When excess cold FA was added, the amount
bound was reduced to background levels. The calculated FA
concentrations over this range of (10–120 nmol/L) were consistent
and none of the values were significantly different (not shown).
The results show that the assay is able to measure FRa over a wide
range of FA concentrations.
In order to determine the minimum amount of serum required,
a normal control serum sample (100 ml) was spiked with KB cell
lysate (5 mg) and different volumes (0–40 mL) were tested for
binding 3H-FA. As shown in a representative example experiment
in Figure 1B, the microfilter assay could detect FA binding in a
volume as little as 10 ml. However above 20 ml of serum, it was
found that the microfilters did not always readily drain. Thus, a
standard volume of 10–20 ml was used for cases and controls.
Although prior work had used 30 KD cutoff filters for
measuring FRa in tissue samples [19], there was a concern that
some loss may have arisen as a consequence of a variation in pore
size, resulting in the presence of some filter pores that would allow
passage of the 38 KDa FRa. Therefore, tests were done
comparing 30 KD and 10 KD cutoff filters. In general, there
were only minor differences. For example, as shown in Figure 1C,
there was no remarkable difference in the bound FA when using
KB cell lysates of KB supernatants. In contrast, small increases
were consistently observed in serum samples when using the
10 KD cutoff filters. Thus, the 10 KD cutoff was used to measure
FRa in the sera of cases and controls.
In an effort to corroborate the microfiltration results, an
immunoprecipitation and immunoblotting method was established. As shown in Figure 1D, FRa can be immunoprecipitated
from sera (100 ml) and immunoblotted resulting in detection of the
38 KD FRa. Overall, these results show that the microfiltration
assay can be used to detect FRa in small sera samples. Further,
immunoblotting analysis reveals the presence of intact full-length
FRa.

were loaded into the upper chamber of a pair of filtration tubes
and diluted to 50 ml total with a solubilizing solution (50 mM Tris,
pH 7.4, 150 mM NaCl, 25 mM n-octyl-b-D-glucopyranoside,
5 mM EDTA, and 0.02% sodium azide). The filtration tubes
were centrifuged and the filters treated with 30 mM acetate
solution (pH 3.0) to remove endogenous FA followed by
centrifugation and two washes with the solubilizing solution. Then
pairs of filtration tubes were incubated either with a 1000X cold
FA in a binding solution (10 mM Na2P4, 1.8 mM KH2PO4,
500 mM NaCl, 2.7 mM KCl, pH 7.4, and 25 mM n-octyl-b-Dglucopyranoside) or with the binding solution alone, and samples
were incubated 2 hours at room temperature and then centrifuged. Binding solution containing 3H-FA was then added to all
samples followed by incubation overnight at 4uC with gentle
agitation. The filters were centrifuged and washed with PBS
containing 50 mM n-octyl-b-D-glucopyranoside to remove the
unbound 3H-FA. Bound 3H-FA retained on the filters was
removed with 100 ml PBS containing 4% Triton X-100 and
transferred into a vial with liquid scintillation cocktail, and the
activity was measured in a Beckman LS6000IC Scintillation
Counter. Specific binding was determined by subtracting the
activity in the presence of excess cold FA from the activity of the
same sample without FA competition.

Immunoprecipitation and immunoblot analysis of FRa
FRa in the serum was directly measured using immunoblot
analysis of immunoprecipitates. Serum samples (100 ml), lysates
(25 mg KB or MCF-7) or KB supernatants were pre-cleared two
times with Protein G Sepharose and 5 mg each of monoclonal
antibodies, MOv18/ZEL and F5753, were added to each sample
and incubated for 1 hour at 4uC. Protein G plus Sepharose beads
were then added and the mixture was allowed to rotate overnight
at 4uC. The beads were then collected with centrifugation and
washed with 600 ml of lysis buffer (20 mM Tris-HCl, pH 7.5,
150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton, and
protease inhibitors). The beads were decanted and boiled in
Laemmli buffer. The proteins were resolved by SDS-PAGE under
non-reducing conditions followed by blotting. The blots were
probed with MOv18/ZEL antibody (5 mg/ml in 2% nonfat dry
milk, 0.1% Tween 20 in TBS) followed by secondary anti-mouse
IgG horseradish peroxidase (HRP) conjugated antibody (1:5000 in
2% non fat dry milk in 0.1% Tween 20), and developed by
enhanced chemiluminescence with Super Signal West Pico
Chemiluminescent Substrate for 5 minutes (Pierce, Rockford, IL,
USA). The blots were then exposed to X-ray film and band
positions and band densities were calculated using a computerized
image analysis system (UVP Biochem Imaging systems, Upland,
CA).

Patients with untreated ovarian cancer have elevated
mean levels of circulating FRa as compared to matched
controls
Patient (i.e. cases) characteristics are detailed in Table 1.
Microfilter binding assays and immunoblotting revealed that sera
derived from the cases contained significantly higher mean levels
of FRa relative to the controls (Figure 2A–C). Linear regression
analysis of all the measurements from both cases and controls
showed that there was a significant correlation between the results
of the microfiltration and immunoblot assays (Figure 2D). To
assess which assay may potentially be more amenable to
development as a biomarker test, cutoffs were established from
the control group values for both assays using the mean and two
standard deviations. With this strategy, greater than 95% of
control values fell below the cutoff. As shown in Figure 3, using
this strategy, 13% and 27% of cases were considered to have
elevated levels of FRa in the microfiltration and immunoblotting
assays, respectively. Statistical analysis using Fisher’s Exact Test
showed that the fraction of cases with elevated levels of FRa, as
detected with the immunoblotting assay, was significantly different
than the fraction of controls considered positive. In contrast, the
fraction of cases detected with the microfiltration assay was not
significant, suggesting that the immunoblotting assay may
potentially have a better positive predictive value.

Statistical Analysis
The mean levels of circulating FRa, detected with either ligandbinding assay or immunoblotting analysis, between cases and
control subjects were compared using the Wilcoxon matched pairs
test. In some cases linear regression analysis was used to examine
for statistically significant correlations. Proportions were tested
using Fisher’s exact test. In all cases, a two-tailed test was used and
a p value of less than or equal to 0.05 was considered significant.

Results
Detection of FRa using microfiltration binding assays and
immunoblotting
In initial efforts to measure levels of circulating FRa by 3H-FA
binding studies, preliminary studies were done to determine the
PLoS ONE | www.plosone.org
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Figure 1. Detection of circulating FRa using microfiltration and
immunoblotting. Panel A: Ten ml aliquots of KB culture supernatant
was diluted to 50 mL with binding buffer that contained increasing
concentrations of 3H-FA pulsed, without (Total bound) or with 1000X
cold FA. After incubation, unbound FA was removed by microfiltration.
Shown are the CPM retained by the microfilter. Also shown is
Background which is binding in the absence of KB supernatants and
without excess cold FA. *p,0.05. Each data point is the mean (6SE) of 3
replicates. The inset dotted line is the linear regression line of the total
bound presented with the corresponding p and r values. Panel B
shows that the amount of specific binding is dependent on the input
levels. In this case increasing amounts of serum containing a KB protein
spike were examined. This experiment is representative of 2 different
experiments. Panel C shows the FA concentration that was bound in
either KB supernatants or a representative serum sample from a case
and control, comparing the 30 KD and 10 cutoff microfilters.
Experiment is representative of two experiments. Panel D shows a
representative example of immunoblot analysis of FRa. Arrow = Mr
38000 protein; KD = kilodalton; IP = immunoprecipitation. Lane 1, IP w
no serum; lane 2, IP of KB lysate; lane 3, IP of precleared serum with KB
lysate spike; lane 4. IP of serum alone, lane 5, KB lysate no IP; lane 6, IP
of KB lysate no serum.
doi:10.1371/journal.pone.0006292.g001

Levels of circulating FRa are comparable between early
and advanced disease
We tested if there was any correlation between the levels of
circulating FRa and a variety of clinical features, as well as FRa
expression within the tumor. We found that circulating FRa levels
(as assessed immunoblotting) were comparable between early
(Stages I/II, n = 15, 1662 au) and advanced stage (Stages III/IV,
n = 15, 1262 au, p = 0.24) patients as shown in Figures 4A. The
differences in circulating FRa between early and advanced stage
patients as assessed by binding assays was also not significant
(1.460.3 vs. 1.060.2. p,0.2, Figure 4B). Importantly, levels of
FRa in early stage patients were significantly higher than all
controls (n = 30, 760.9 au, immunoblotting, p,0.0001 and
0.660.1 nmols/l binding, p = 0.02).
No significant correlations between circulating FRa and either
age, grade, recurrence status or extent of debulking (optimal vs.
sub-optimal) were observed (p.0.05). Tumors from 27 of 30
patients had high FRa expression, consistent with prior work, and
therefore, our sample size was not large enough to determine if
tumor FRa expression was associated with levels of FRa in the
blood. However, of the three tumors (1 serous borderline and 2
mucinous borderline) with low tumor-associated FRa, only 1
mucinous borderline demonstrated low circulating FRa levels.
This suggests that circulating FRa may not correlate well with
tumor levels. Indeed, in our prior studies, we observed some
discrepancies in FRa staining different tumor foci (recurrent and
metastatic lesions) [14].

Discussion
Ovarian cancer often eludes detection because of the lack of
definitive early symptoms. Hence, ovarian cancer presents at
advanced stage in ,70% of patients. The biomarkers in use today
are not adequate for detection of early stage cancer. Therefore, it
is not surprising that ovarian cancer is the number one cause of
death among all of the gynecological malignancies in recent years.
Currently available markers CA-125 and proteomic profiles lack
sensitivity, specificity and/or reproducibility. There is clear need
for diagnostic markers to detect ovarian cancer at early stages. A
molecule expressed nearly exclusively in pathogenic tissue would
make an ideal biomarker and one such promising candidate is
folate receptor (FR-a). FR-a is highly overexpressed in the vast
majority of ovarian cancers but exhibits limited expression in
PLoS ONE | www.plosone.org
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Figure 2. Patients with ovarian cancer have elevated levels of circulating FRa as compared to matched controls. Panel A shows the
number of circulating folate receptor (FRs) extrapolated from the microfiltration assay assuming a 1:1 molar ratio of FA:FR in both the cases and
matched controls Panel B shows the densitometric signal obtained using immunoblotting. P values in panels A and B are calculated using the
Wilcoxon’s matched pairs test and each bar represents the mean6s.e.m. Panel C: Lane 1, immunoprecipitation negative control; lane 2, negative
control (MCF-7) lysate; lane 3, positive control (KB) lysate); lane 4, control serum sample; lane 5, matched ovarian cancer serum sample; lane 6, control
serum sample; lane 7 matched ovarian cancer serum sample. Arrow = Mr 38000 protein; KD = kilodalton. Panel D shows the linear regression analysis
correlating the microfiltration binding assay data and the immunoblotting data. Each data point represents a unique individual. Open symbols
represent the healthy controls and closed symbols are patients.
doi:10.1371/journal.pone.0006292.g002

upregulation of FRa may occur early in ovarian carcinogenesis in
some patients. Indeed, Toffoli and colleagues found that nearly
79% of patients with early stage (I and II) ovarian cancer
overexpressed FRa, which was essentially identical to the
proportion of advanced stage patients that had FRa expression
[9]. We observed in our studies that levels of circulating FRa in
early stage patients was not different than advanced stage patients.
However, Toffoli and colleagues found that while the proportion
was similar, the levels of FRa on the tumor were significantly

tissues that are responsible for whole body retention of folates (e.g.,
the placenta, choroid plexus and kidney). In the current study, we
tested whether it was feasible to detect circulating FRa in ovarian
cancer patients and whether the circulating FRa was full-length
and functional.
Our data show that patients with ovarian cancer have elevated
levels of FRa relative to healthy controls. These results suggest that
circulating FRa could potentially be developed as a biomarker.
The increased levels of FRa in early stage disease indicates that

Figure 3. Immunoblotting may have a better positive predictive value than microfiltration assays. Panel A and B show the percentage
of cases and controls that were considered positive by microfiltration or immunoblotting assay, respectively, with cutoffs established as the mean
plus two standard deviations of the control values. The p-value was calculated using the Fisher’s Exact Test.
doi:10.1371/journal.pone.0006292.g003
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FRs may bind and interfere with clinical efficacy. This might
explain high failure rates observed in some FRa-directed
immunotherapies in patients with ovarian cancer. For example,
Kershaw and colleagues developed an approach in which
autologous T cells from patients were gene-modified with a
chimeric receptor that contained a FRa-specific single chain
antibody coupled to the Fc receptor gamma chain [21]. While the
cells secreted IFN-c in response to FRa, they failed to localize to
tumor site, a failure that may be explained by circulating FRa
which saturated the chimeric receptors. Therefore, analysis of
circulating FRa in cancer patients might help in determining levels
of anti-FRa targeted chimeric receptors needed for successful
therapy. In addition, we also found that elevated circulating FRa
was functional, suggesting potential interference with a number of
folic acid-conjugated drug therapies that have been developed that
require a functional binding site [20], One of the difficulties,
however, in measuring serum levels of FRa is the lack of a quality
assay. While our binding assays were able to detect a difference
between cases and controls, the results obtained suggest that
immunoblotting assay may be potentially more useful in detecting
elevated levels. However, like with any blotting assay, the utility is
limited by its technical complexity (i.e. immunoprecipitation
followed by immunoblotting) and the results with this assay are
only semi-quantitative.
In conclusion, our results demonstrate that ovarian cancer
patients, including those with early disease, have elevated levels of
functional intact FRa as compared to healthy controls. With
further development, including larger early stage ovarian cancer
sample sizes and improved assay performance, the use of FRa as a
biomarker for ovarian cancer may be feasible.

Figure 4. Levels of circulating FRa are similar in early and late
stage ovarian cancer patients. Panels A and B shows the
comparison between early and late stage densitometric and microfiltration assay signals, respectively. Each data point represents a unique
individual and the horizontal line represents the mean. p values shown
were calculated using a Student’s T test.
doi:10.1371/journal.pone.0006292.g004

higher in the advanced stage patients. The lack of correlation may
indicate that there are other factors regulating serum levels. For
example, Mantovani and colleagues found that normal human
urine samples were strongly positive for FRa immune reactivity,
suggesting that there is a mechanism for its rapid kidney clearance
[15]. Since the proximal tubules of the kidney strongly express the
protein, one might conclude that the kidney has a well developed
strategy to eliminate FRa to prevent it from accumulating in the
blood and preventing FA uptake into tissues [19]. This is
supported in kinetic murine modeling studies which have shown
that as the tumor progresses, rise in urine levels of FRa precede
sera levels considerably [15].
Intact FRa is a 38 kDa protein and in our immunoblot assay,
anti-MOv18/ZEL antibody detected a protein at the same
molecular weight. Furthermore, we showed that the microfiltration assay detected functional protein, which taken together
suggests that FRa shed by ovarian cancer is intact and functional.
The presence of FRa in the circulation of patients has therapeutic
significance as a number of therapies have been developed that
target cell surface FRa in cancer patients [20]. These circulating
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